Latest expert network news

Stay up to date with the latest news from Techspert, and read updates and insights from the many industries we work in

Featured

Techspert's Milestone Achievement in the Financial Times 1000 List

Techspert's recognition as the 539th placement in the Financial Times 1000: Europe’s Fastest Growing Companies underscores our commitment to revolutionizing how expert insights are accessed and applied in the healthcare and life sciences sectors....

Latest Posts

View all

Company News

Techspert Secures Second Consecutive Financial Times 1000 Win

Techspert has once again secured its place among Europe’s fastest-growing companies in the Financial Times FT1000 ranking. This marks the second consecutive year we’ve been recognized for our primary research platform in healthcare and life sciences, a reflection of both our growth and the impact we’re making.

Company News

Featured

Techspert Welcomes Andrew Graham as New Chairman

We are thrilled to announce the appointment of Andrew Graham as the new Chairman of Techspert. With a stellar track record in the finance and tech industries, Andrew brings a wealth of experience and a fresh perspective to our company. His appointment marks a significant milestone for Techspert as we continue to drive innovation and expand our reach in the healthcare and life sciences sectors.

Oncology

Featured

Expert Q&A

Expert Q&A: Why Personalized Medicine Is Transforming Oncology – and What It Means for the Market

Personalized medicine is reshaping cancer treatment, offering new ways to target the disease based on each patient’s unique genetic profile. Unlike traditional chemotherapy - which broadly targets cancer cells but often harms healthy tissue - personalized treatments hone in on the specific pathways driving an individual’s cancer. Dr. Tong Dai, a board-certified oncologist with over a decade of experience, has dedicated his career to advancing these targeted therapies. His work spans leading-edge research and hands-on patient care, including pivotal clinical trials that helped bring breakthrough immunotherapies like Keytruda to patients with difficult-to-treat cancers.